Filana Therapeutics, Inc. filed a Form 8-K on September 22, 2026, disclosing that the U.S. Food and Drug Administration lifted the full clinical hold on its investigational new drug application for simufilam in tuberous sclerosis complex-related epilepsy.

Key Highlights

  • Clinical hold lifted: The FDA removed the full clinical hold on Filana's IND application for simufilam targeting TSC-related epilepsy, as announced September 22, 2026.
  • Phase 2a trial design: The planned study is a 16-week multicenter, randomized, double-blind trial evaluating two doses of simufilam in patients with refractory TSC-related seizures.
  • Trial scope: The study is planned at 13 U.S. sites with a target enrollment of 40 subjects aged 12 to 55.
  • Extension study available: All subjects who complete the double-blind treatment phase are eligible to participate in a 48-week extension study.
  • Patient screening timeline: Patient screening is expected to begin by the first quarter of 2027, according to the filing.
  • Trial readiness: The company disclosed it has engaged a clinical research organization, identified trial sites, recruited potential investigators, and has investigational drug supply in place.

Filana Therapeutics Advances Simufilam Phase 2a Study Following FDA Hold Removal

According to the Form 8-K filed with the SEC by Filana Therapeutics, Inc. (NASDAQ:FLNA) on September 22, 2026, the FDA has lifted the full clinical hold on the company's IND application for simufilam, clearing the path to initiate a planned Phase 2a proof-of-concept study in tuberous sclerosis complex-related epilepsy. The company stated that implementation of the Phase 2a study is "now able to progress expeditiously toward site initiation and patient enrollment."

The filing describes the Phase 2a trial as a 16-week multicenter, randomized, double-blind study designed to evaluate two doses of simufilam in patients with refractory TSC-related seizures, to be conducted at 13 U.S. sites with a target enrollment of 40 subjects aged 12 to 55. The study is designed to assess safety, tolerability, pharmacokinetics, and seizure-related measures, including seizure frequency, seizure intensity and duration, nighttime seizures, and sleep-related outcomes. Subjects completing the double-blind phase are eligible for a 48-week extension study.

The company reported completing key trial-readiness activities during the clinical hold period, including engaging a leading clinical research organization, identifying clinical trial sites, and recruiting potential investigators, with investigational drug supply already in place. According to the filing, data from the study are expected to help inform the development path for simufilam in TSC-related epilepsy, "including the design of future studies in younger patient populations." The filing notes that statements regarding timing and trial plans are forward-looking and subject to risks described in the company's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent regulatory filings.

What Was Disclosed

Filana Therapeutics disclosed the FDA's removal of a full clinical hold on its simufilam IND for TSC-related epilepsy, outlined the Phase 2a trial design and readiness status, and indicated patient screening is expected to begin by the first quarter of 2027.